Granocyte-colony stimulating factor (G-CSF) has significant efficacy as secondary prophylaxis of chemotherapy-induced neutropenia in patients with solid tumors: Results of a prospective study

Anticancer Research

Volumn 33, Issue 1, 2013, Pages 301-308

  Freyer, Gilles ^a,b   Jovenin, Nicolas ^b   Yazbek, Gabriel ^b   Villanueva, Christian ^c   Hussain, Amal ^d   Berthune, Anne ^e   Rotarski, MacIej ^f   Simon, Hélène ^g   Boulanger, Vincent ^h   Hummelsberger, Michael ⁱ   Falandry, Claire ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b INSTITUT JEAN GODINOT   (France)

^c Hospital of Besancon   (France)

^d Regional Hospital of Quimper   (France)

^e Center René Huguenin   (France)

^f Oncology Center of Pays Basque   (France)

^g Morvan Teaching Hospital   (France)

^h Department of Medical Oncology   (France)

ⁱ Department of Medical Oncology   (France)

Author keywords

Chemotherapy induced neutropenia; Febrile neutropenia; G CSF; Pegfilgrastim; Secondary prophylaxis

Indexed keywords

BEVACIZUMAB; BIOSIMILAR AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHEMOTHERAPY INDUCED NEUTROPENIA; DRUG EFFICACY; DRUG INDUCED DISEASE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEOPLASM; NEUTROPENIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; SECONDARY PREVENTION;

EID: 84873019788     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kuderer NM, Dale DC, Crawford J, Coster LE and Lyman GH: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258-2266, 2006.
2. Courteney DM, Aldeen AZ, Gorman SM, Handler JA, Trifilio SM, Parada JP, Yarnold PR and Bennett CL: Cancer-associated neutropenic fever: Clinical outcome and economic costs of emergency department care. Oncologist 12: 1019-1026, 2007.
3. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EB.C, Shih YT, Ensor J, Bekele BN, Gralla RJ, Talcott JA and Rolston K: Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26: 606-611, 2008.
4. Chabner BA: Antimitotic drugs. Cancer Chemother Biol Response Modif 14: 55-56, 1993.
5. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party: EORTC guidelines for the use of granulocyte-colony stimulating factors to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433-2453, 2006.
6. National Comprehensive Cancer Network: Practice Guidelines in Oncology V1.2012. Myeloid Growth Factors. Available at: http://www.nccn.or/professionals/ physician-gls/PDF/myeloid-gr owth.pdf. Last accessed October 20, 2012.
7. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grons J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M and Glaspy J: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325: 164-170, 1991.
8. Dale D: Current management of chemotherapy-induced neutropenia: The role of colony-stimulating factors. Semin Oncol 30: 3-9, 2003.
9. Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM and Crawford J: Acute myeloid leukemia or myelodysplasic syndrome in randomized clinical trials of cancer chemotherapy with granocyte colony-stimulating factor: a systemic review. J Clin Oncol 28: 2914-2924, 2010.
10. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford JC, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer A, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ and Wolff AC: 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelines. J Clin Oncol 24: 3187-3205, 2006.
11. Aapro M, Crawford J and Kamioner D: Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony stimulating factors: Where are we now? Support Care Cancer 18: 529-541, 2010.
12. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M and Verhoef G: Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87: 277-283, 2008.
13. Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, Garcia-Garre E, Martin P, Bosch A and Lluch A: Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients Breast Cancer Res Treat 114: 479-484, 2009
14. Pettengell R, Schwenkglenks M and Bosly A: Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 87: 429-430, 2008.
15. Falandry C, Campone M, Cartron G, Guerin D and Freyer G: Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer 46: 2389-2398, 2010.
16. Balducci L, Al-Halawani H, Charu V, Tam J, Shalin S, Dreiling L and Ershler WB: Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12: 1416-1424, 2007.
17. Kuderer NM, Dale DC, Crawford J and Lyman GH: Impact of primary prophylaxis with granulocyte colony stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systemic review. J Clin Oncol 25: 3158-3167, 2007.
18. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R and Lyman G: Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: A meta-analysis of randomized controlled trials. Curr Med Res Opin 23: 2283-2295, 2007.